Abstract
Two hundred fifty-nine patients with ovarian cancers were treated with the combination of CDDP, aclarubicin and tegafur. Ninety-seven of them had macroscopic diseases during the combination chemotherapy, and the overall anti-tumor response rate (CR + PR) for these patients was 54.6%. It was 60.0% for the 80 cases with epithelial ovarian cancer among them. The median survival time for the antitumor responders was 18 months, against 7 months for the non-responders and 18 months for 103 patients with advanced ovarian cancer (stage III-IV).
Publication types
-
Clinical Trial
-
English Abstract
-
Multicenter Study
MeSH terms
-
Aclarubicin / administration & dosage
-
Adolescent
-
Adult
-
Aged
-
Aged, 80 and over
-
Antineoplastic Combined Chemotherapy Protocols / therapeutic use*
-
Cisplatin / administration & dosage
-
Combined Modality Therapy
-
Drug Evaluation
-
Female
-
Follow-Up Studies
-
Humans
-
Japan
-
Middle Aged
-
Multicenter Studies as Topic
-
Ovarian Neoplasms / drug therapy*
-
Ovarian Neoplasms / mortality
-
Ovarian Neoplasms / surgery
-
Prognosis
-
Remission Induction
-
Reoperation
-
Tegafur / administration & dosage
Substances
-
Tegafur
-
Aclarubicin
-
Cisplatin